Patrick J. Beyer

President and Chief Executive Officer (CEO) at CONMED

Board

Since January 1, 2025

Age

59 years

Education

Holds a Bachelor of Arts in Economics from Kalamazoo College, an MBA in Finance from Western Michigan University, and completed the Advanced Management Program at Harvard Business School.

Tenure

Joined CNMD in December 2014 as President of CONMED International, later promoted to oversee International and Global Orthopedics in October 2020, advanced to COO in April 2024, and assumed the role of President and CEO effective January 1, 2025.

Also at CONMED

Brent Lalomia

Vice President, Quality Assurance, Regulatory Affairs, Customer Experience, and Logistics

Edward Clifford

Vice President, Global Manufacturing

John Ferrell

Executive Vice President, Human Resources

About

The executive is 59 years old and holds a strong educational background with a Bachelor of Arts in Economics from Kalamazoo College, an MBA in Finance from Western Michigan University, and completion of the Advanced Management Program at Harvard Business School.

Beginning his career at CNMD in December 2014 as President of CONMED International, he advanced through multiple leadership roles. His tenure included a promotion to oversee International and Global Orthopedics in October 2020, followed by an appointment as Chief Operating Officer in April 2024, culminating in his current role as President and Chief Executive Officer effective January 1, 2025.

Before joining CNMD, he accumulated extensive experience in the healthcare industry, including a 21-year leadership tenure at Stryker Corporation and serving as CEO at ICNet. His background is further enhanced by his board memberships, notably with Bioventus, underscoring a robust career in strategic and operational roles within the medical sector.

$CNMD Performance Under Patrick J. Beyer

Past Roles

Organization	Role	Date Range	Details
CNMD	Chief Operating Officer (COO)	Starting April 2024	Held role before becoming President and CEO
CNMD	President, International and Global Orthopedics	October 2020 to April 2024	Included additional responsibility for the U.S. Orthopedics business
CNMD	President of CONMED International	December 2014 to October 2020	Served in this role prior to further leadership transitions
ICNet	Chief Executive Officer (CEO)	2010 to 2014	Privately held infectious control software company; sold in 2014
Stryker Corporation	Led Stryker Europe	2005 to 2009	Leadership role in Europe
Stryker Corporation	Led Stryker UK, South Africa, and Ireland	2002 to 2005	Leadership role covering multiple regions
Stryker Corporation	Led Stryker Medical	1999 to 2002	Leadership role in the medical division

External Roles

Organization	Role	Date Range	Details
Bioventus	Board Member (Audit Committee)	N/A	Member of Audit Committee
Axenic	Board Member	N/A	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount (USD)	Payment Schedule	Additional Details
Base Salary	$548,926	Annual	Paid in British pounds; converted to U.S. dollars using an exchange rate of £0.7868 to $1.00
401(k) Employer Contributions	$0	N/A	Not provided; Mr. Beyer participates in a UK program instead of a U.S.-based 401(k)
Benefits Restoration Plan	$0	N/A	Does not receive contributions under the Benefits Restoration Plan
Other Fixed Payments	$545,070	Annual	Includes retirement plan payments, car allowance, car repairs, personal air travel costs, and more

Performance Compensation

Data from FY 2023

Non-Equity Incentive Compensation (Executive Bonus)

Performance Metric	Threshold (%)	Target (%)	Maximum (%)	Actual Performance (% of Target)
Net Sales (FX Adjusted)	4.80	24.00	48.00	109.7
Adjusted Diluted Net EPS	6.40	32.00	64.00	150.0
Free Cash Flow	0.80	4.00	8.00	135.0
Commercial Goals	4.00	20.00	40.00	59.4
Overall Bonus	16.00	80.00	160.00	114.5

Bonus Target: 80% of base salary
Actual Bonus Payout: 91.6% of base salary, amounting to $505,300

Equity Awards

Stock Options

Component	Grant Date	Number of Options	Exercise Price (USD)	Vesting Schedule	Expiration Date	Additional Details
Stock Options	March 1, 2023	32,212	$96.16	20% vesting annually over 5 years	March 1, 2033	Grant date fair value of $1,274,951

Performance Stock Units (PSUs)

Component	Grant Date	Target Units	Vesting Schedule	Performance Metrics	Payout Range	Additional Details
PSUs	March 1, 2023	2,920	Cliff vest after 3-year performance period	Relative TSR vs. S&P Healthcare Equipment Select Index	Threshold (25th percentile): 50% payout; Target (50th percentile): 100% payout; Maximum (75th percentile+): 200% payout	Grant date fair value of $425,064

Evaluation Period: 2023 for the non-equity bonus with performance measured against preset financial metrics.

Note: The stock options are time-based awards, whereas the PSUs incorporate performance thresholds tied to the company’s relative Total Shareholder Return (TSR) compared to its industry benchmark.